

Speaker Lecture Titles

Partial list of confirmed speakers.

Name	Country	Lecture Title
Claudio A. Cuello	Canada	TBA
Johannes Attems	UK	DEMENTIA WITH LEWY BODIES AND PARKINSON'S DISEASE; SAME LEWY BODIES BUT DIFFERENT DISEASES
Kaj Blennow	Sweden	BLOOD AND CSF BIOMARKERS FOR AD - THE PATH TO IMPLEMENTATION IN CLINICAL ROUTINE
Mathew Blurton Jones	USA	EXAMINING THE THERAPEUTIC POTENTIAL OF STEM CELL DERIVED MICROGLIA
Guojun Bu	USA	APOE-TREM2 AXIS IN MICROGLIAL RESPONSES AND ALZHEIMER'S DISEASE
Luc Buee	France	NANOBODIES/VHH, AN ALTERNATIVE TO ANTI-TAU IMMUNOTHERAPY
Frédéric Checler	France	SPREADING OF APP-DERIVED FRAGMENTS: NEW TOOLS, NEW DATA
Gaël Chételat	France	ALZHEIMER'S DISEASE BRAIN LESION TOPOGRAPHY AND PROPAGATION
Ornit Chiba-Falek	USA	APOE-TARGETED EPIGENOME THERAPY: TOWARDS PRECISION MEDICINE IN ALZHEIMER'S DISEASE
Jeffrey Cummings	USA	THE ALZHEIMER'S DISEASE DRUG DEVELOPMENT PIPELINE: THE CHANGING LANDSCAPE OF TREATMENTS AND TRIALS
Bart De Strooper	Belgium	PRESENILIN/Γ-SECRETASE ALLOSTERIC MODULATORS: TOO LATE FOR PRECISION MEDICINE IN ALZHEIMER'S DISEASE?
Marc Diamond	USA	TAU PROPAGATION INTO CELLS AND THROUGH NETWORKS
Karen Duff	UK	TAUOPATHY MECHANISMS IN FTD AND AD
Dustin Mergott	USA	DISCOVERY AND EARLY CLINICAL DEVELOPMENT OF ORAL ANTI-TAU THERAPIES AS THE NEXT GENERATION OF DISEASE-MODIFYING TREATMENTS
Nick Fox	UK	"PARADOXICAL" CEREBRAL VOLUME CHANGES ON MRI IN ANTI-AMYLOID IMMUNOTHERAPY TRIALS: POSSIBLE EXPLANATIONS AND PLAUSIBILITY
Dan Frenkel	Israel	TARGETING METABOLIC CHANGES IN ASTROCYTES TOWARDS THERAPEUTIC INTERVENTION IN ALZHEIMER'S DISEASE
Giovanni Frisoni	SWITZERLAND	INTERVENTIONS FOR SECONDARY PREVENTION IN BRAIN HEALTH SERVICES FOR DEMENTIA
Luz Frolich	Germany	CLINICAL MEANINGFULNESS OF CLINICAL TRIAL DATA IN EARLY ALZHEIMER'S DISEASE
James Galvin	USA	PRECISION MEDICINE APPROACHES TO ENHANCE STUDIES OF BRAIN HEALTH AND THE RISK OF ALZHEIMER'S DISEASE
Angela Genge	Canada	THERAPEUTIC INNOVATIONS IN ALS
Klaus Gerwert	Germany	MISFOLDING OF ALPHA-SYNUCLEIN AS EARLY BIOMARKER FOR PARKINSON'S DISEASE AND SYNUCLEINOPATHIES
Alison Goate	USA	GENETIC RISK FOR AD: WHAT THIS TELLS US ABOUT MECHANISM OF DISEASE
Gabriel Gold	Switzerland	MICROINFARCTS AND MICROBLEEDS: THE SEARCH FOR MECHANISMS
Christian Haass	Germany	POSITIONING MICROGLIAL FUNCTION AND DYSFUNCTION WITHIN THE AMYLOID CASCADE
Oskar Hansson	Sweden	USE OF NOVEL BIOMARKERS FOR NEURODEGENERATIVE DISEASES IN CLINICAL TRIALS AND PRACTICE
Elizabth Head	USA	ALZHEIMER DISEASE IN PEOPLE WITH DOWN SYNDROME - THE FUTURE OF CLINICAL TRIALS
Susanne Hendrix	USA	AN OVERVIEW OF CLINICAL TRIAL RESULTS IN ALZHEIMER'S DISEASE IN THE PAST 2 DECADES WITH A FOCUS ON TIME SAVINGS
Michael Heneka	Germany	MICROGLIAL METABOLISM DETERMINES AMYLOID BETA CLEARANCE FUNCTION
Joachim Herz	USA	TARGETING ENDOSOMAL PH HOMEOSTASIS FOR AD PREVENTION
Makoto Higuchi	Japan	ASSOCIATION AND DISSOCIATION BETWEEN NEUROIMAGING-BASED AND PLASMA BIOMARKERS FOR AD
Henne Holstege	The Netherlands	ESCAPING DEMENTIA UNTIL EXTREME AGES: WHAT CAN COGNITIVELY HEALTHY CENTENARIANS TEACH US?

David Holtzman	USA	APOE3CH INFLUENCES THE MICROGLIAL RESPONSE TO AB PLAQUES AND SUPPRESSES AB-INDUCED TAU SEEDING AND SPREADING
Bradley Hyman	USA	DRIVERS OF DISEASE PROGRESSION
Costantino Iadecola	USA	NEUROVASCULAR DETERMINANTS OF NEURODEGENERATION: FROM MECHANISMS TO THERAPIES
Ole Isacson	USA	LIPID DYSHOMEOSTASIS MECHANISMS IN LEWY BODY DEMENTIA AND ALZHEIMER'S DISEASE
Takeshi Iwatsubo	Japan	PREDICTION OF BRAIN AMYLOID PET STATUS BY PLASMA AMYLOID-B42 AND P-TAU217 BIOMARKERS IN THE JAPANESE PRECLINICAL AD COHORT
Clifford Jack	USA	UPDATE ON NIA AA RESEARCH FRAMEWORK
William Jagust	USA	OPTIMAL OUTCOMES IN COGNITIVE AGING
Jung-Hwan Shin	Korea	DEVELOPMENT OF A VIDEO-BASED MONITORING PLATFORM FOR COMPREHENSIVE MOTOR SYMPTOMS OF PARKINSON'S DISEASE
Mia Kivipelto	Sweden	PRECISION PREVENTION OF ALZHEIMER'S DISEASE: NEW DISCOVERIES FROM THE FINGERS TRIALS
Lynn Kramer	USA	NOVEL APPROACHES TO CLINICAL DEVELOPMENT AND THE FUTURE POTENTIAL OF SIMULATED PLACEBO
Frank Laferla	USA	MODELING LATE-ONSET ALZHEIMER'S DISEASE IN MICE
Virginia Lee	USA	MODULATORS OF TAUOPATHIES
Seung-Jae Lee	Korea	INHIBITION OF NEURON-TO-OLIGODENDROCYTE ALPHA-SYNUCLEIN PROPAGATION WITH AN ANTI-TLR2 ANTIBODY
Cynthia Lemere	USA	POTENTIAL MECHANISMS AND MITIGATION STRATEGIES FOR ANTI-AMYLOID-INDUCED ARIA
Frank Longo	USA	MODULATION OF THE P75 NEUROTROPHIN RECEPTOR INHIBITS MICROGLIAL DYSTROPHY AND DYSFUNCTION ASSOCIATED WITH PATHOLOGICAL FORMS OF TAU
Daniel M. Michaelson	Israel	ASSESSMENT OF THE ANTI APOE4 EFFICACY OF THE RECENTLY DEVELOPED ABCA1 ACTIVATOR N1
Eliezer Masliah	USA	NEUROIMMUNE MODULATORY PATHWAYS IN THE THERAPEUTICS OF LEWY BODY DEMENTIA
Mark Mintun	USA	ADVANCES IN OUR UNDERSTANDING OF AMYLOID PLAQUE CLEARING THERAPIES
Asuka Morizane	Japan	CELL THERAPY FOR PARKINSON'S DISEASE WITH PLURIPOTENT STEM CELL-DERIVED DOPAMINERGIC PROGENITORS
John Morris	USA	EXPLORING RACIAL DIFFERENCES IN ALZHEIMER DISEASE
Ulrike Müller	Germany	NEUROTROPHIC AND SYNAPTOTROPHIC FUNCTIONS OF SECRETED APPS AND ITS THERAPEUTIC POTENTIAL FOR AD
Melissa Murray	USA	DEMOGRAPHIC AND GENETIC CONTRIBUTORS TO CORTICOLIMBIC VULNERABILITY IN YOUNG-ONSET AD
Manuela Neumann	Germany	ROLE OF TDP-43 PHOSPHORYLATION IN TDP-43 PROTEINOPATHIES
Henrietta Nielsen	Sweden	PERIPHERAL APOE SIGNATURES
Agneta Nordberg	Sweden	TRACKING AD SUBTYPE TRAJECTORIES WITH MULTI-MODAL PET AND FLUID BIOMARKERS
Tiago Outerio	Germany	MODELING AND IMAGING ALPHA-SYNUCLEIN AGGREGATION: INSIGHTS INTO MOLECULAR MECHANISMS OF DISEASE
Ronald Petersen	USA	ALZHEIMER'S DISEASE BIOMARKERS IN THE COMMUNITY
Werner Poewe	Austria	PD RISK SCREENING - WHERE DO WE STAND
Marco Prado	Canada	CHOLINERGIC MECHANISMS IN DEMENTIA
Gill Rabinovici	USA	IMPLEMENTING BIOMARKERS IN REAL WORLD MEMORY CARE: LESSONS FROM THE IDEAS STUDY
Laura Ranum	USA	INCREASED ALZHEIMER'S RISK ASSOCIATED WITH INTRONIC CASP8 REPEAT EXPANSION
Philip Scheltens	The Netherlands	AD THERAPY; WHERE DO WE GO FROM HERE??
Michael Schlossmacher	Canada	GENERATION OF ALPHA-SYNUCLEIN AGGREGATES IN HUMAN OLFACTORY EPITHELIA INCLUDES MUCUS-PRODUCING GLANDS
Menachem Segal	Israel	PRESENILIN-1 AFFECTS MITOCHONDRIA IN CULTURED HIPPOCAMPAL NEURONS: FUNCTIONAL IMPLICATIONS
Jie Shen	USA	LRRK2 MUTATIONS AND PARKINSON'S DISEASE
Tamara Shiner	Israel	GENETIC FACTORS IN CLINICAL, IMAGING AND BLOOD BIOMARKERS IN DLB
Sam Sisodia	USA	THE GUT MICROBIOME AND IMPACT ON AD-TYPE NEUROPATHOLOGY

Beka Solomon	Israel	DOWN-REGULATION OF BACE1 ACTIVITY WITHOUT AFFECTING PROCESSING OF OTHER SUBSTRATES MAY HAVE A CLINICAL VALUE FOR TREATMENT OF ALZHEIMER'S DISEASE
Mona Soreq	Israel	SEX-SPECIFIC DECLINES IN CHOLINERGIC-TARGETING TRNA FRAGMENTS IN THE NUCLEUS ACCUMBENS IN ALZHEIMER'S DISEASE
Maria Grazia Spillantini	UK	ALPHA-SYNUCLEIN MODELS
Peter St. George-Hyslop	Canada	TREM2 SIGNALLING PATHWAYS IN MICROGLIA AND PERIPHERAL BLOOD MONONUCLEAR CELLS
Stephen Salloway	USA	APPROPRIATE USE OF AMYLOID-LOWERING TREATMENTS
Beth Stevens	USA	MODELING MECHANISMS OF AD RISK AND RESILIENCE
Fabrizio Stocchi	Italy	HOW PARKINSON'S DISEASE TREATMENT WILL CHANGE IN THE NEXT FUTURE
Tom Sudhof	USA	ABETA AND SYNAPSES: A CONTENTIOUS RELATIONSHIP
Malu Tansey	USA	TARGETING AGE-RELATED IMMUNE DYSFUNCTION TO REDUCE RISK OF NEURODEGENERATION
Rudy Tanzi	USA	THE ROLE OF PERIPHERAL CELLS AND FACTORS IN ALZHEIMER'S DISEASE PATHOGENESIS
Charlotte Teunissen	The Netherlands	IDENTIFICATION OF NOVEL PROTEINS AND PROTEIN PANELS IN BODY FLUIDS BY PROTEOMICS FOR VARIOUS DEMENTIA DIAGNOSES (FAMILIAL AD, AD, DLB, FTD, A+SCD). A STRATEGY TOWARDS CLINICAL USE
Li-Huei Tsai	USA	NEUROIMMUNE INTERACTIONS AT THE BRAIN BORDERS IN HEALTH AND DISEASE
Robert Vassar	USA	LOW-LEVEL BACE1 INHIBITION FOR ALZHEIMER DISEASE
Michael Weiner	USA	COMMUNITY ENGAGED RESEARCH USING DIGITAL MARKETING, WEB BASED ASSESSMENTS, AND BLOOD TESTS TO RECRUIT AND SCREEN UNDER REPRESENTED PEOPLE INTO THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI)
Cheryl Wellington	Canada	TBA
Donna Wilcock	USA	UNDERSTANDING MECHANISMS OF ANTI-AMYLOID IMMUNOTHERAPY-MEDIATED ARIA EVENTS
Bengt Winblad	SWEDEN	DEVELOPMENT OF SMALL MOLECULES TARGETING TAU AND OTHER PROTEINS IN ALZHEIMER DISEASE
Henrik Zetterberg	Sweden	NOVEL BIOFLUID-BASED BIOMARKERS FOR NEURODEGENERATIVE PROCESSES ACROSS DEMENTIAS
Berislav Zlokovic	USA	BLOOD-BRAIN BARRIER AND VASCULAR SYSTEM AS TREATMENT TARGETS FOR COGNITIVE IMPAIRMENT AND ALZHEIMER'S' DISEASE